Since COVID-19 cases escalated to pandemic levels worldwide, Damon Runyon scientists are contributing to the unprecedented global effort to stop the disease by investigating how this specific coronavirus enters human cells, developing more efficient testing and searching for a treatment. 

Co-Authored by Damon Runyon Fellow Caroline Bartman, PhD, and Sponsor Joshua Rabinowitz, MD, PhD, and published in the New York Times 

As with any other poison, viruses are usually deadlier in larger amounts.

Damon Runyon Board Member Elaine V. Fuchs, PhD, the Rebecca C. Lancefield Professor of Mammalian Cell Biology and Development at The Rockefeller University, has received the 2020 Canada Gairdner Award in recognition of her pioneering work on tissue stem cells, the cells of our tissues that are responsible for repairing wounds. 

We’re thrilled to welcome Judy Swanson to the Damon Runyon Board of Directors this year. Judy is passionate about encouraging science and innovation at all levels, which is one of the reasons she supports Damon Runyon. Judy has been a member of the Damon Runyon Bay Area Committee since January 2017.

While parents have been coaxing kids to eat more vegetables for generations, only recently have researchers delved into understanding the science behind the health benefits. Elizabeth S. Sattely, PhD (Damon Runyon Fellow ‘08-‘10), has been at the forefront of this trend to harness plant chemistry to improve human health.

From all of us at the Damon Runyon Cancer Research Foundation, we sincerely hope that you are safe and healthy. We are aware that everyone is affected by COVID-19/novel coronavirus, from our scientists to our donors. 

After decades of trying, scientists developed drugs that target one of the most elusive cancer-causing proteins, KRAS, which is activated in nearly a third of cancers, including difficult to treat lung and colorectal cancers. In 2016, Piro Lito, MD, PhD, (Damon Runyon Clinical Investigator ‘17-’20) and his colleagues at Memorial Sloan Kettering Cancer Center showed that a compound could shut down the most common form of the KRAS mutation in lung cancer without harming healthy cells.

Advances in Genome Biology and Technology (AGBT) and the Damon Runyon Cancer Research Foundation have partnered to award a new fellowship in honor of world-renowned genomics pioneer, Elaine R. Mardis, PhD. Steven W. M. Crossley, PhD, at the University of California, Berkeley, will receive this award during the AGBT General Meeting to be held February.

Written by Yung S. Lie, PhD, President and Chief Executive Officer, Damon Runyon Cancer Research Foundation

Twenty-two brilliant early career investigators will receive funding to pursue cutting-edge cancer research.